Rate My Professor Jarad Martin

Professor Martin's research integrates clinical practice with advanced studies in hypofractionated radiotherapy, stereotactic body radiotherapy for oligometastases, quality assurance protocols, urethral sparing techniques, and imaging-guided treatments for prostate, bladder, rectal, and oesophageal cancers. He collaborates with multidisciplinary teams and groups like TROG Cancer Research and Laureate Professor Rob Sanson-Fisher’s team to translate research into practice. With over 85 peer-reviewed publications, notable works include senior authorship on the Australasian guidelines for prostate cancer radiotherapy; "DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)" (2022, Journal of Clinical Oncology); "Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial" (2025); and leadership in trials such as TROG 15.01 SPARK, TROG 18.01 NINJA, and PROFIT. His contributions have earned awards including the Canadian Young Oncology Investigator of the Year (2006), Ray Bush Prize (2006), ASCO Merit Award (2006), TROG Orchid Prize (2007), and Chris Atkinson Award for Best Scientific Paper (2012). Through these efforts, Martin advances radiotherapy precision and patient outcomes in oncology.